Diabetes epidemiology as a tool to trigger diabetes research and care

Diabetologia

Volumn 42, Issue 5, 1999, Pages 499-518

  Zimmet, P Z ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Classification; Criteria; Epidemic; Epidemiology; Insulin resistance; Leptin; Metabolic syndrome; Type II diabetes

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; LEPTIN; PANCREAS ISLET CELL ANTIBODY;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EPIDEMIC; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SCREENING;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; PROTEINS; RESEARCH;

EID: 0032966682     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051188     Document Type: Review

References (150)

1. Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications (1979) Diabetes Care 2: 63-226
2. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057
3. World Health Organization Expert Committee on Diabetes Mellitus (1980) Second Report. Technical Report Series 646, WHO, Geneva
4. Major RM (1954) A history of medicine. Blackwell, Oxford, p 67
5. Zimmet PZ (1995) The pathogenesis and prevention of diabetes in adults. Diabetes Care 18: 1050-1064
6. World Health Organization Study Group on Prevention of Diabetes Mellitus (1994) Technical Report Series No 844, WHO Geneva
7. World Bank (1993) World Development Report 1993: Investing in Health. World Development Indicators. Oxford University Press, Oxford
8. National Diabetes Data Group (1995) Diabetes in America. US Dept. of Health and Human Services, PHS
9. Colaguiri S, Colaguiri R, Ward J (1998) National Diabetes Strategy and Implementation Plan. Diabetes Australia, Canberra
10. West KM (1978) Epidemiology of diabetes and its vascular lesions. Elsevier, New York
11. The World Health Organization Multinational Study of Vascular Disease in Diabetics. (1985) Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. Diabetologia 28 [Suppl]: 615-640
12. Sharp CL, Butterfield WJH, Keen H (1964) Diabetes survey in Bedford, 1962. Proc R Soc Med 57: 193-204
13. Bennett PH, Burch TA, Miller M (1971) Diabetes mellitus in American (Pima) Indians. Lancet ii: 125-128
14. Zimmet P, Taft P, Guinea A, Guthrie W, Thoma K (1977) The high prevalence of diabetes mellitus on a Central Pacific island. Diabetologia 13: 111-115
15. Zimmet P, Dowse G, Finch C, Serjeantson S, King H (1990) The epidemiology and natural history of NIDDM - lessons from the South Pacific. Diabetes Metab Rev 6: 91-124
16. King H, Rewers M (1993) World Health Organization Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 16: 157-177
17. O'Dea K (1991) Westernisation, insulin resistance and diabetes in Australian Aborigines. Med J Aust 155: 258-264
18. Zimmet P (1992) Challenges in diabetes epidemiology - from West to the Rest. Diabetes Care 15: 232-252
19. McCarty D, Amos A, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 [suppl 5]: S1-S85
20. de Courten M, Bennett PH, Tuomilehto J, Zimmet P (1997) Epidemiology of NIDDM in Non-Europids. In: Alberti KGMM, Zimmet P, DeFronzo RA (eds) International textbook of diabetes mellitus. 2nd edn. Wiley, Chichester, pp 143-70
21. Songer TJ, Zimmet P (1995) Epidemiology of Type 2 diabetes: an international perspective. PharmacoEconomics 8 [suppl 1]: 1-11
22. Dowse GK, Gareeboo H, Zimmet PZ (1990) High prevalence of NIDDM and impaired glucose intolerance in Indian, Creole and Chinese Mauritians. Diabetes 39: 390-396
23. Tan CE, Emmanuel SC, Tan B-Y, Jacob E (1999) Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore National Health Survey. Diabetes Care 22: 241-247
24. Chou P, Chen H, Hsiao K (1992) Community-based epidemiological study on diabetes in Pu-Li, Taiwan. Diabetes Care 15: 81-89
25. Shanghai Diabetes Research Cooperative Group (1980) Diabetes Mellitus Survey in Shanghai. Chin Med J 93: 663-672
26. Pan X-R, Yang W-Y, Li G-W, Liu J, The National Diabetes Prevention and Control Cooperative Group (1997) Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 20: 1664-1669
27. Pan CY, Lu JM, Tian H et al. (1996) Study of the prevalence of diabetes mellitus in the Shougang Corporation in Beijing. Diabet Med 13: 663-668
28. Himsworth HP (1936) Diabetes mellitus: its differentiation into insulin-sensitive and insulin insensitive types. Lancet i: 117-120
29. McCarthy MI, Froguel P, Hitman GA (1994) The genetics of non-insulin-dependent diabetes mellitus: tools and aims. Diabetologia 37: 959-968
30. Groop L (1997) The molecular genetics of non-insulin dependent diabetes mellitus. J Intern Med 241: 95-100
31. World Health Organization Study Group on Diabetes Mellitus (1985) Technical Report Series No 727, WHO Geneva
32. Alberti KGMM, Zimmet PZ (1998) New diagnostic criteria and classification of diabetes - again? Diabet Med 15: 535-536
33. Zimmet P, Turner R, McCarty D, Rowley M, Mackay IR (1999) Crucial points at diagnosis - NIDDM or slow IDDM Diabetes Care 22: in press
34. Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of Type 2 diabetes in youth. Diabetes Care 22: 345-354
35. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183-1197
36. Alberti KGMM, Zimmet PZ for the World Health Organization Consultation (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional Report of a WHO Consultation. Diabetic Med 15: 539-553
37. Kuzuya T, Matsuda A (1997) Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 20: 219-220
38. DeFronzo RA, Bonadonna RC, Ferrannini E (1997) Pathogenesis of NIDDM. In: Alberti KGMM, Zimmet P, DeFronzo RA (eds) International textbook of diabetes mellitus. 2nd edn. Wiley, Chichester, pp 635-712
39. Hattersley AT (1998) Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med 15: 15-24
40. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42: 358-362
41. Mølbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J (1994) Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 11: 650-655
42. Zimmet PZ, Tuomi T, Mackay R et al. (1994) Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11: 299-303
43. Tuomilehto J, Zimmet P, Mackay IR et al. (1994) Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before the clinical onset of the disease. Lancet 343: 1383-1385
44. UK Prospective Diabetes Study (UKPDS) (1991) VIII Study design, progress and performance. Diabetologia 34: 877-890
45. Gleichmann H, Zörcher B, Greulich B et al. (1984) Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults. Diabetologia 27: 90-92
46. Groop LC, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 35: 237-241
47. Willis JA, Scott RS, Brown LJ et al. (1996) Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Res Clin Pract 33: 89-97
48. Zimmet PZ, Shaten BJ, Kuller LH, Rowley MJ, Knowles WJ, Mackay IR (1994) Antibodies to glutamic acid decarboxylase and diabetes mellitus in the multiple risk factor intervention trial. Am J Epidemiol 140: 683-690
49. Hagopian WA, Karlsen AE, Gottsater A et al. (1993) Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 65K autoantibody positivity at onset predicts diabetes type. J Clin Invest 91: 368-374
50. Niskanen LN, Tuomi T, Karjalainen J, Groop LC, Uusitupa MIJ (1995) GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 18: 1557-1565
51. Wroblewski M, Gottsater A, Lindgarde F, Fernlund P, Sundkvist G (1998) Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 21: 250-255
52. Turner R, Stratton I, Manley S et al. (1997) UKPDS2: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288-1293
53. Beischer NA, Wein P, Sheedy MT, Mackay IR, Rowley MJ, Zimmet P (1995) Prevalence of antibodies to glutamic acid decarboxylase in women who have had gestational diabetes. Am J Obstet Gynecol 173: 1563-1569
54. Füchtenbusch M, Ferber K, Standl E, Ziegler AG, and participating centers (1997) Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening. A Prospective Multicenter Study. Diabetes 46: 1459-1467
55. Horton V, Stratton I, Bottazzo GF et al. for the UK Prospective Diabetes Study (UKPDS) Group (1999) Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes. Diabetologia 42: 608-616
56. King H, Senator G, Zimmet P, Harris A (1986) The Tasmanian insulin-treated diabetes register. Inception and progress in the first 12 months. Med J Aust 144: 414-416
57. Humphrey ARG, McCarty DJ, Mackay IR, Rowley MJ, Dwyer T, Zimmet P (1998) Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus. Diabet Med 15: 113-119
58. Zimmet PZ, Elliott RB, Mackay IR et al. (1994) Autoantibodies to glutamic acid decarboxylase and insulin in presymptomatic insulin-dependent diabetes mellitus: frequency and segregation by age and gender. Diabet Med 11: 866-871
59. Feeney SJ, Myers MA, Rowley MJ (1997) Evaluation of ICA512 autoantibodies in combination with other islet cell autoantibodies at the onset of insulin dependent diabetes mellitus. Diabetes Care 20: 1403-1407
60. Whittingham S, Byron S, Tuomilehto J et al. (1997) Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women. Diabet Med 14: 678-685
61. Eastman R, Javitt J, Herman W, Dasbach E, Harris M (1996) Prevention strategies for non-insulin-dependent diabetes mellitus: an economic perspective. In: Le-Roith D, Taylor S, Olefsky J (eds) Diabetes mellitus: a fundamental and clinical text. Lippincott-Raven Publishers, New York, pp 621-630
62. Vionnet N, Stoffel M, Takeda J et al. (1992) Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes. Nature 356: 721-722
63. Bell GI, Xiang K-S, Newman MV et al. (1991) Gene for noninsulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc Natl Acad Sci USA 88: 1484-1488
64. Yamagata K, Oda N, Kaisaki PJ et al. (1996) Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY 3). Nature 384: 455-458
65. Yamagata K, Furuta H, Oda N et al. (1996) Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY 1). Nature 384: 458-460
66. Waterston R, Sulston JE (1998) The Human Genome Project: reaching the finishing line. Science 282: 53-54
67. de Courten M, Zimmet P (1997) Screening for non-insulin-dependent diabetes mellitus: where to draw the line. Diabet Med 14: 95-98
68. Zimmet P, de Courten M, Alberti KGMM (1998) New classification and criteria for diabetes - moving the goalposts closer. Editorial Med J Aust 168: 593-594
69. Rushforth NB, Bennett PH, Steinberg AG, Burch TA, Miller M (1971) Diabetes in the Pima Indians. Evidence of bimodality in glucose tolerance distributions. Diabetes 20: 756-765
70. Zimmet P, Whitehouse S, Alford F, Chisholm D (1978) The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance. Diabetologia 15: 23-27
71. Pettitt D, Knowler W, Lisse J, Bennett P (1980) Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians. Lancet ii: 1050-1052
72. Finch CF, Zimmet PZ, Alberti KGMM (1990) Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentrations? Diabet Med 7: 603-610
73. Charles MA, Fontbonne A, Thibult N, Warnet J-M, Rosselin GE, Eschwege E (1991) Risk factors for NIDDM in white population. Diabetes 40: 796-799
74. Charles MA, Balkau B (1996) Revision of diagnostic criteria for diabetes (Letter). Lancet 348: 1657-1658
75. De Vegt F, Dekker JM, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ (1998) The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance. Diabetes Care 21: 1686-1690
76. Unwin N, Alberti KGMM, Bhopal R, Harland J, Watson W, White M (1998) Comparison of the current WHO and new ADA criteria for the diagnosis of diabetes mellitus in three ethnic groups in the UK. Diabet Med 15: 554-557
77. Gimeno SGA, Ferreira SRG, Franco LJ, Iunes M (1998) The Japanese-Brazilian Diabetes Study Group: comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. Diabetes Care 21: 1889-1892
78. Shaw JE, Zimmet PZ, de Courten M et al. (1999) Impaired fasting glucose or imparied glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care 22: 399-402
79. Dowse G, Zimmet P, Alberti K (1996) Screening for diabetes and glucose intolerance. In: Alberti K, Zimmet P, DeFronzo R, Keen HH (eds) International textbook of diabetes mellitus. 2nd edn, vol 2. Wiley, London, pp 1687-1707
80. Harris MI, Modan M (1994) Screening for NIDDM: why is there no national program? Diabetes Care 17: 440-444
81. American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21: 296-309
82. Harris MI (1993) Undiagnosed NIDDM; clinical and public health issues. Diabetes Care 16: 642-652
83. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-819
84. Fontbonne A, Charles MA, Thibult N et al. (1991) Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 34: 356-361
85. Nathan DM (1993) Long term complications of diabetes mellitus. N Engl J Med 328: 1676-1685
86. Pettitt DJ, Knowler WC, Baird R, Bennett PH (1980) Gestational diabetes: infant and maternal complications of pregnancy in relation to third-trimester glucose tolerance in the Pima Indians. Diabetes Care 3: 458-464
87. Diabetic Control and Complications Trial Research Group (1993) The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329: 977-986
88. Schatz D, Rogers DG, Brouhard BH (1996) Prevention of insulin-dependent diabetes mellitus: an overview of three trials. Cleve Clin J Med 63(5): 270-274
89. Gale EA (1996) Theory and practice of nicotinamide trials in pre-Type 1 diabetes. J Pediatr Endocrinol Metab 9: 375-379
90. Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG (1998) Delay of type 1 diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 41: 536-541
91. Tisch R, Liblau RS, Yang X-D, Liblau P, McDevitt HO (1998) Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 47: 894-899
92. Yamata H, Uchigata Y, Kawasaki E (1998) Onset age-dependent variations of three islet specific autoantibodies in Japanese IDDM patients. Diabetes Res Clin Pract 39: 211-217
93. Pozzilli P (1998) Prevention of insulin-dependent diabetes mellitus 1998. Diabetes Metabol Rev 14: 69-84
94. Skyler J, Marks J (1993) Immune Intervention In Type I Diabetes Mellitus. Diabetes Reviews 1 (1): 15-42
95. Tuomi T, Carlsson A, Haiyan L et al. (1999) Clinical and genetic characteristics of Type 2 diabetes with and without GAD antibodies. Diabetes 48: 150-157
96. Hamman RF (1997) Epidemiology of microvascular complications. In: Alberti KGMM, Zimmet P, DeFronzo RA (eds) International textbook of diabetes mellitus. 2nd edn. Wiley, Chichester, pp 1293-1319
97. Pirart J (1978) Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed 1947 and 1973. Diabetes Care 21: 168-88; 252-263
98. Reichard P, Nilsson BY, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-309
99. Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117
100. UK Prospective Diabetes Study Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
101. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713
102. Panzram G (1987) Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 123-131
103. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-1607
104. Zimmet P (1989) Non-insulin-dependent (Type 2) diabetes mellitus - does it really exist? Diabet Med 6: 728-735
105. Pyorälä K, Pedersen TR, Kjeksus J, Faergerman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620
106. Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335: 1001-1009
107. Niskanen LK, Penttilä I, Parviainen M, Uusitupa MIJ (1996) Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care 19: 486-493
108. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK (1990) Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263: 2893-2898
109. McPhillips JB, Barrett-Conner E, Wingard DL (1990) Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 131: 443-453
110. Zimmet P, Alberti KGMM (1997) The changing face of macrovascular disease in non-insulin dependent diabetes mellitus in different cultures: an epidemic in progress. Lancet 350 [Suppl 1]: S1-S4
111. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432
112. Halaas JL, Gajiwala KS, Maffei M et al. (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546
113. Considine RV, Sinha MK, Heiman ML et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295
114. Zimmet P, Hodge A, Nicholson M et al. (1996) Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. BMJ 313: 965-969
115. O'Rahilly S (1998) Life without leptin. Nature 392: 330-331
116. Auwerx J, Staels B (1998) Leptin. Lancet 351: 737-742
117. Neel JV (1962) Diabetes mellitus: a thrifty genotype rendered detrimental by 'progress'? Am J Hum Genet 14: 353-362
118. O'Dea K, Zimmet P (1993) Thrifty genotypes. In: Leslie RDG (ed) Causes of diabetes. Wiley, Chichester pp 269-290
119. de Courten M, Zimmet P, Hodge A et al. (1997) Hyperleptinaemia: the missing link in the Metabolic Syndrome? Diabet Med 14: 200-208
120. Tritos NA, Mantzoros CS (1997) Leptin: its role in obesity and beyond. Diabetologia 40: 1371-1379
121. Hodge AM, Dowse GK, Zimmet PZ, Collins VR (1995) Prevalence and secular trends in obesity in Pacific and Indian Ocean island populations. Obes Res 3 [Suppl. 2]: S77-S87
122. Hodge AM, de Courten MP, Zimmet PZ (1997) Leptin levels do not predict weight gain: a prospective Study. Diabetologia 40 [Suppl 1]: A262(abstract)
123. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J (1982) High plasma insulin as coronary heart disease risk factor. In: Eschwege E (ed) Advances in diabetes epidemiology. INSERM Symposium No 22. Elsevier, Amsterdam, pp 143-148
124. Collins VR, Dowse GK, Finch CF, Zimmet PZ (1990) An inconsistent relationship between insulin and blood pressure in three Pacific island populations. J Clin Epidemiol 43: 1369-1378
125. Segal KR, Landt M, Klein S (1996) Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 45: 988-991
126. Zimmet PZ, Collins VR, de Courten MP et al. (1998) Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Int J Obes Relat Metab Disord 21: 171-177
127. Leyva F, Godsland IF, Ghatei M et al. (1997) Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18: 928-933
128. Fürnsinn C, Brunmair B, Furtmüller R, Roden M, Englisch R, Waldhäusl W (1998) Failure of leptin to affect basal and insulin-stimulated glucose metabolism of rat skeletal muscle in vitro. Diabetologia 41: 524-529
129. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG (1997) Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138: 3395-3401
130. Koyama K, Chen G, Wang M-Y et al. (1997) β-cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes 46: 1276-1279
131. Wang J, Liu R, Hawkins M, Barzllai N, Rossetti L (1998) A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 393: 684-688
132. Haffner SM, Miettinen H, Mykkänen L, Karhapää P, Rainwater DL, Laakso M (1997) Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 21: 393-399
133. Couillard C, Lamarche B, Mauriège P et al. (1998) Leptinemia is not a risk factor for ischemic heart disease in men. Diabetes Care 21: 782-786
134. Collier G, Walder K, Lewandowski P, Sanigorski A, Zimmet P (1997) Leptin and the development of obesity and diabetes in Psammomys obesus: Obes Res 5: 455-458
135. Walder K, Pilippis A, Clark S, Zimmet P, Collier G (1997) Leptin inhibits insulin binding in isolated rat adipocytes. J Endocrinol 155: R5-R7
136. Walder K, Willet M, Zimmet P, Collier GR (1997) Ob (obese) gene expression and leptin levels in Psammomys obesus. Biochimica et Biophysica Acta 1354: 272-278
137. Hales CN, Barker DJP (1992) Type 2 (non-insulin-dependent) diabetes mellitus: The thrifty phenotype hypothesis. Diabetologia 35: 595-601
138. Hales CN, Barker DJP, Clark PMS, Cox IJ, Fall C, Osmond C (1991) Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303: 1019-1022
139. Yajnik CS, Fall CHD, Vaidya U et al. (1995) Fetal growth and glucose and insulin metabolism in four-year-old Indian children. Diabet Med 12: 330-336
140. Ravelli ACJ, van der Meulen JHP, Michels RPJ et al. (1998) Glucose tolerance in adults after prenatal exposure to famine. Lancet 351: 173-177
141. Poulsen P, Vaag AA, Kyvik KO, Møller Jensen D, Beck-Nielsen H (1997) Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia 40: 439-446
142. Stanner SA, Bulmer K, Andrès C et al. (1997) Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study. BMJ 315: 1342-1349
143. Waldhäusl W, Fasching P (1993) Fetal growth and impaired glucose tolerance in men and women. Diabetologia 36: 973-974
144. McCance DR, Pettit DJ, Hanson RL, Jacobsson LTH, Knowler WC, Bennett PH (1994) Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ 308: 942-945
145. Dowse GK, Zimmet PZ, Alberti KGMM (1993) Infant nutrition and subsequent risk of Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 267-268.
146. Joseph KS, Kramer MS (1996) Review of the evidence on fetal and early childhood antecedents of adult chronic disease. Epidemiol Rev 18: 158-174
147. Dungar DB, Ong KKL, Huxtable SJ et al. (1998) Association of the INS VNTR with size at birth. Nat Genet 19: 98-100
148. Pan X, Li G, Hu Y et al. (1997) Effect of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544
149. Dowse GK, Gareeboo H, Alberti KGMM et al. (1995) Changes in population cholesterol concentrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention programme in Mauritius. BMJ 311: 1255-1259
150. Uusitalo U, Feskens EJM, Tuomilehto J et al. (1996) Fall in total cholesterol concentration over five years in association with changes in fatty acid composition of cooking oil in Mauritius: cross sectional survey. BMJ 313: 1044-1046